12.16.25 -- The Top 10 Nations Redrawing The Outsourcing Map

By integrating AI and mechanistic models into early design, developers can overcome productivity limits and accelerate timelines for complex therapeutic modalities.

Delve into the increasing necessity for carefully designed development platforms to deliver cutting-edge AAV therapies efficiently and safely to patients.

Gain a deeper understanding of full capsid kinetics, how process intensification improves patient safety, and how tech can be harnessed for scalable gene therapy production.

The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

Early, phase-appropriate CMC planning is critical for advanced therapy success. Proactively managing regulatory risks and applying Quality by Design principles secures a clear path to market.

A panel of experts share potential pitfalls and lessons learned from their many years of experience across a wide array of projects in the cell and gene therapy space.

Unlock the potential of AAV manufacturing by leveraging data-driven insights and the advanced Pro10™ platform to optimize processes, enhance productivity, and drive innovation in cell and gene therapy.

Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.

By utilizing an engineered co-transcriptional capping RNA Polymerase, researchers can reduce the production of double-stranded RNA byproducts and enhance the functionality of mRNA therapeutics.

Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies.

Since 2024, multiple cell and gene therapy programs faced regulatory delays due to manufacturing deficiencies, highlighting the critical need for robust CMC strategies and inspection-ready operations.

Discover how precision fill/finish processes ensure the safety, sterility, and success of cutting-edge viral vector therapies as they move from production to patients.

Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

This comprehensive exploration aims to shed light on the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

Pharmaceutical labeling demands precision. Examine key considerations for ensuring accuracy and efficiency in your process, from robust control systems to diverse printing options.

Learn how a biotech company, facing a tight timeline and budget, scaled up its production from the lab to a full commercial site using a strategic operational readiness approach.

See how the iCELLis500+ fixed-bed bioreactor supports the scalable manufacturing of both AAV and oncolytic virus therapies, detailing successful process development and scale-up strategies.

Our combined offering aims to increase speed-to-therapy by increasing connectivity between providers and hub patient services, enabling seamless care coordination and patient engagement.

Whether you are advancing RNA-based therapeutics or exploring next-generation nanomedicine, understanding the properties of ionizable lipids is crucial to unlocking the full potential of LNP delivery.

We provide a complete range of bioanalytical solutions, including method development, validation and transfer; PK and PD Bioanalysis, ELISA and multiplex assays, bioassays, and immunogenicity testing.

LipidBrick® Cell Ready enables efficient CRISPR delivery for TCR knockout in T cells, improving viability and expansion over electroporation, with optimized RNA ratios and liposome volumes.

The Curator™ adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.